SCHEMBL20109767

SCHEMBL20109767

O=C(O)CNC(=O)c1ncc2nc(-c3cccc(Br)c3)ccc2c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 17/20 0.57
FTO Q9C0B1 5/20 0.51
KDM5B Q9UGL1 3/20 0.51
KDM2A Q9Y2K7 3/20 0.51
BBOX1 O75936 2/20 0.45
TET3 O43151 1/20 0.45
VEGFA P15692 1/20 0.45
FLT1 P17948 1/20 0.45
ASPH Q12797 1/20 0.45
TET2 Q6N021 1/20 0.45
KDM8 Q8N371 1/20 0.45
OGFOD1 Q8N543 1/20 0.45
TET1 Q8NFU7 1/20 0.45
EGLN3 Q9H6Z9 1/20 0.45
HIF1AN Q9NWT6 1/20 0.45
KDM6B O15054 2/20 0.45
KDM4C Q9H3R0 1/20 0.45
KDM3A Q9Y4C1 1/20 0.45
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20109765 0.88 EGLN1 (0.67) EGLN1FTOKDM5BKDM2ABBOX1
SCHEMBL20109766 0.88 EGLN1 (0.61) EGLN1FTOKDM5BKDM2ABBOX1
SCHEMBL19917277 0.88 EGLN1 (0.61) EGLN1FTOKDM5BKDM2ABBOX1
SCHEMBL20109771 0.88 EGLN1 (0.62) EGLN1FTOKDM5BKDM2ABBOX1
SCHEMBL19917240 0.87 EGLN1 (0.58) EGLN1FTOKDM5BKDM2ABBOX1
SCHEMBL20109775 0.85 EGLN1 (0.62) EGLN1FTOBBOX1ASPHKDM8
SCHEMBL19895134 0.84 EGLN1 (0.63) EGLN1FTOKDM5BKDM2ABBOX1
SCHEMBL19917251 0.81 EGLN1 (0.58) EGLN1FTOKDM5BKDM2A
SCHEMBL19895136 0.81 MAPT (0.41) EGLN1ALDH1A1LMNA
SCHEMBL20109772 0.81 EGLN1 (0.58) EGLN1FTOKDM5BKDM2ABBOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994566-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) 2018-06-12 US disclosed
US-9994566-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) 2018-06-12 US disclosed
US-20180118738-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) 2018-05-03 US disclosed
US-20180118738-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118738-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF HIF1AN, EGLN3, EGLN2 EGLN1 7/4885FTO 1038/4885KDM5B 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.